| 000 | 01843 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517132311.0 | ||
| 264 | 0 | _c20170608 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1365-2141 | ||
| 024 | 7 |
_a10.1111/bjh.14342 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVarghese, Abraham M | |
| 245 | 0 | 0 |
_aEradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _c02 2017 |
||
| 300 |
_a573-582 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 | _aBone Marrow Examination |
| 650 | 0 | 4 | _aConsolidation Chemotherapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xdrug therapy |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHoward, Dena R | |
| 700 | 1 | _aPocock, Christopher | |
| 700 | 1 | _aRawstron, Andy C | |
| 700 | 1 | _aFollows, George | |
| 700 | 1 | _aMcCarthy, Helen | |
| 700 | 1 | _aDearden, Claire | |
| 700 | 1 | _aFegan, Christopher | |
| 700 | 1 | _aMilligan, Donald | |
| 700 | 1 | _aSmith, Alexandra F | |
| 700 | 1 | _aGregory, Walter | |
| 700 | 1 | _aHillmen, Peter | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 176 _gno. 4 _gp. 573-582 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.14342 _zAvailable from publisher's website |
| 999 |
_c26739273 _d26739273 |
||